Friday, March 17, 2017 1:03:46 AM
Several AZN-based tweets from attendees at the SGO convention[in suburban Washington, D.C.] the past few days suggested that there is a need for an early detection and diagnostic means for ovarian cancer...patients in later stages of ovarian cancer have not survived well, if at all:
http://insider.foxnews.com/2017/02/03/robert-kraft-donald-trump-friendship-super-bowl
The content of the following links suggests there is a proof-of-concept solution to that problem, from researchers at UTSW, that is not yet widely known---it is based on "exosome" technology:
http://www.exosome-rna.com/proof-of-concept-data-for-a-novel-exosome-based-cancer-detection-platform-published/
See the Abstract, Introduction, and description[note the reference to 100% accuracy in ability to distinguish active tumor cells from benign cells from normal cells present in a blood sample] accompanying fig.4 of the above referenced article set forth here:
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=14795&path%5B%5D=47251
All cancers might be detected and diagnosed using the blood sampling means/technique described above, according to the UTSW researchers:
http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/utsd-2932.pdf
See particularly Table 1 and Examples 6-8 of the authors' published patent application:
http://tinyurl.com/gqvwkga
Previously, I had sent[February 2017] the gist of the above to 1) the Bidens at their foundation, 2)Joy Drake at OCRFA.org, for distribution to colleagues at the Ovarian Cancer Research Fund Alliance, 3) Dr.Jon LaPook at CBS news, 4) contacts I have at BMGF, 5) Dr. Jedd Wolchok at MSKCC and a few others. I interspersed my comments as appropriate to each of above. I have met and talked with Dr. Wolchok previously at his Wistar lecture in Philadelphia in early December 2016.
My purposes: to try to create publicity, and perhaps funding, to bring the proof-of-concept research of Dr. Schroit et al at UTSW 1) to any fruition, and 2) to the attention of members of the public that might be interested. I have no idea whether/if/when those purposes have been, or will be, fulfilled.
Recent AZN News
- Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca • GlobeNewswire Inc. • 05/06/2024 06:00:00 AM
- CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial • Business Wire • 05/02/2024 11:00:00 AM
- AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio • Business Wire • 05/01/2024 11:05:00 AM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow • Business Wire • 04/29/2024 11:00:00 AM
- AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • PR Newswire (US) • 04/25/2024 12:00:00 PM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings • IH Market News • 04/25/2024 11:52:46 AM
- Q1 2024 results • Business Wire • 04/25/2024 06:00:00 AM
- IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial • Business Wire • 04/16/2024 11:00:00 AM
- Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News • IH Market News • 04/12/2024 11:05:29 AM
- Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News • IH Market News • 04/11/2024 11:24:54 AM
- FASENRA approved for treatment of children aged 6 to 11 with severe asthma • Business Wire • 04/11/2024 11:00:00 AM
- ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors • Business Wire • 04/06/2024 03:10:00 AM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors • Business Wire • 04/06/2024 01:43:00 AM
- IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial • Business Wire • 04/05/2024 11:00:00 AM
- Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer • Business Wire • 04/02/2024 11:00:00 AM
- Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer • Business Wire • 04/02/2024 06:00:00 AM
- VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH • Business Wire • 04/01/2024 11:00:00 AM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
- Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News • IH Market News • 03/26/2024 11:20:49 AM
- ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) • Business Wire • 03/25/2024 11:00:00 AM
- Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More • IH Market News • 03/19/2024 11:33:10 AM
- AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer • Business Wire • 03/19/2024 11:00:00 AM
- AstraZeneca to acquire Fusion for $2 billion • IH Market News • 03/19/2024 10:52:44 AM
- AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio • Business Wire • 03/18/2024 11:00:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM